JUAN IGNACIO ARENAS MIRAVE-rekin lankidetzan egindako argitalpenak (105)

2020

  1. Efficacy and safety of the combination of pravastatin and sorafenib for the treatment of advanced hepatocellular carcinoma (Estahep clinical trial)

    Cancers, Vol. 12, Núm. 7, pp. 1-14

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

2015

  1. Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España

    Gastroenterologia y Hepatologia, Vol. 38, Núm. 4, pp. 263-273

  2. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  3. Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities

    European Journal of Gastroenterology and Hepatology, Vol. 27, Núm. 1, pp. 46-54

  4. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis

    Liver International, Vol. 35, Núm. 1, pp. 90-100

  5. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

    Journal of Viral Hepatitis, Vol. 22, Núm. 5, pp. 469-480

2013

  1. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice

    Annals of Hepatology, Vol. 12, Núm. 2, pp. 205-212

2012

  1. Accurate fat fraction quantification by multiecho gradient-recalled-echo magnetic resonance at 1.5 T in rats with nonalcoholic fatty liver disease

    European Journal of Radiology, Vol. 81, Núm. 6, pp. 1122-1127

  2. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening

    New England Journal of Medicine, Vol. 366, Núm. 8, pp. 697-706

  3. Effect of neoadjuvant chemotherapy in hepatic steatosis

    Chemotherapy, Vol. 58, Núm. 2, pp. 89-94

  4. Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models

    Cancer Cell International, Vol. 12

2011

  1. Celsior Versus University of Wisconsin Preserving Solutions for Liver Transplantation: Postreperfusion Syndrome and Outcome of a 5-Year Prospective Randomized Controlled Study

    World Journal of Surgery

2010

  1. Biochemical determination of lipid content in hepatic steatosis by the Soxtec method

    World Journal of Gastroenterology, Vol. 16, Núm. 12, pp. 1495-1499

  2. Colorectal cancer prognosis twenty years later

    World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867

  3. Inflammatory mediators of hepatic steatosis

    Mediators of Inflammation, Vol. 2010

  4. Niveles plasmóticos de la vitamina B12 y ácido fólicoenpacientes con hepatopatía crónica

    Gastroenterologia y Hepatologia, Vol. 33, Núm. 4, pp. 280-287

  5. Outcome of liver transplantation using donors older than 60 year of age

    Clinical Transplantation, Vol. 24, Núm. 4, pp. 543-549

2009

  1. Trends in Barrett's esophagus diagnosis in Southern Europe: Implications for surveillance

    Diseases of the Esophagus, Vol. 22, Núm. 3, pp. 239-248

2008

  1. Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis

    World Journal of Gastroenterology, Vol. 14, Núm. 10, pp. 1521-1527